ADMA Stock Risk & Deep Value Analysis
ADMA Biologics Inc
DVR Score
out of 10
What You Need to Know About ADMA Stock
We analyzed ADMA Biologics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ADMA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is ADMA Stock?
Overall Risk
Moderate
Financial Risk
Medium
Market Risk
Low
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Medium
What Are the Red Flags for ADMA?
- ⚠
Lower-than-expected Q1 2026 earnings or cautious FY2026 guidance (Q2 2026)
- ⚠
Increased competitive pressure or pricing erosion from larger players
- ⚠
Slower-than-anticipated plasma center ramp-ups or collection volume growth
- ⚠
Supply chain disruptions impacting plasma fractionation
Unlock ADMA Red Flags & Risk Warnings
Create a free account to see the full analysis
Is ADMA Stock Undervalued?
Unlock the full AI analysis for ADMA
Get the complete DVR score, risk analysis, and more
Does ADMA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
4 Identified
The moat is strengthening due to increasing vertical integration, which reduces external supply reliance and costs, coupled with a differentiated product and the high regulatory and capital intensity of the plasma industry. This makes it difficult for new entrants to compete effectively.
Moat Erosion Risks
- •Aggressive pricing strategies from larger, established competitors
- •Emergence of a superior therapeutic alternative to IVIG
- •Regulatory changes impacting plasma collection or product approval processes
ADMA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive ADMA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April 2026)
- •Announcement of 2-3 new plasma center openings in Q2 2026
- •Updated FY2026 revenue and margin guidance
Medium-Term (6-18 months)
- •Continued significant increases in plasma collection volumes and capacity utilization (H2 2026 - H1 2027)
- •Potential strategic partnership for international market expansion (late 2026)
- •Completion of debt refinancing to further reduce interest expenses and enhance flexibility (early 2027)
Long-Term (18+ months)
- •Achievement of significant market share in the U.S. IVIG market (2028-2029)
- •Potential approval for additional indications for ASCENIV or new product pipeline advancement (2029+)
- •Becoming a key player in the global plasma-derived therapeutics market (2030+)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ADMA?
- ✓
Acceleration in gross margin expansion and sustained positive operating cash flow
- ✓
Consistent reporting of new plasma center openings and increasing plasma collection volumes
- ✓
Successful execution of debt reduction or refinancing efforts
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ADMA (ADMA Biologics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
